PCV13 Cost-Effectiveness of Apixaban Compared to Low Molecular Weight Heparin/ Edoxaban for Treatment and Prevention of Recurrent Venous Thromboembolism  by Lanitis, T et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A375
Objectives: Resistant hypertension (RH) is highly associated with cardiovascular 
risks. The difficulty in enrolling large numbers of study participants limits stud-
ies on treatment effects of RH. This study aims to compare the effectiveness of 
triple antihypertensive combination therapy for RH patients in Taiwan. MethOds: 
Patients who had 3 antihypertensive agents of different classes concurrently pre-
scribed in outpatient clinics with their medication possession ratio ≧ 0.7 during 
2004-2006 were identified as the RH cases from the National Health Insurance 
Research database. The 1st outpatient visit with 3 antihypertensive agents of dif-
ferent classes being prescribed was defined as the index date. Patients were further 
classified into two treatment groups according to the combination of antihyper-
tensive therapy; the A+B+C group was defined as those who received concurrent 
therapy of ACEI/ARB in combination with beta-blocker and CCB, and the A+C+D 
group was those who received ACEI/ARB together with CCB and diuretics. The 
Cox proportional regression analysis was performed to investigate the risk of 
major adverse cardiovascular events (MACE) between the two treatment groups. 
Subgroup analysis was further performed by classifying patients into those with 
or without previous history of stroke, myocardial Infarction or end stage renal 
diseases. Results: There were 13,551 patients identified as the prevalence cases 
of RH during 2004-2006. Results showed the A+C+D group had a lower risk of 
MACE when compared to the A+B+C of group (adjusted HR= 1.11; 95%CI 1.01-1.22; 
p= 0.0272). Subgroup analysis showed there was no significant difference in the risk 
of MACE between the A+B+C and the A+C+D groups either in patients with prior 
disease history (adjusted HR = 1.10; 95%CI 0.96-1.25; p= 0.1881) or without prior 
disease history (adjusted HR = 1.12; 95%CI 0.99-1.28; p= 0.0767). cOnclusiOns: 
The A+C+D combination therapy seemed to be more effective than the A+B+C 
therapy in preventing MACE among patients with RH.
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Objectives: Randomized trials have shown that blockade of beta adrener-
gic receptors leads to symptomatic improvement, reduced hospitalization and 
enhanced survival in many patients with heart failure (HF) and reduced ejec-
tion fraction. The objective of this study was to compare beta blockers for their 
efficacy in reducing mortality. MethOds: A systematic literature search for 
randomized clinical trials for use of beta blockers in HF was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was col-
lected for the study type, methods, country and key findings. Extracted study 
data included study design, patient charatcertristcis and primary outcomes. A 
bayesian random effects network meta-analysis (NMA) model was developed in 
WinBUGS14. Results: We identified 830 references and found 21 randomized 
trials in 23,122 patients with 3,871 events. The treatments included in our study 
were Enalapril (E), Metoprolol (M), Atenolol (A), Bisoprolol (Bi), Bucindolol (Bu), 
Carvedilol (C), Metoprolol (M), Nebivolol (N) and placebo (P). All beta-blockers ver-
sus placebo were effective in reducing mortailty in HF and reduced ejection frac-
tion patients. Carvedilol ranked the highest with a Surface Under the Cumulative 
RAnking curve (SUCRA) score of 0.8672, Atenolol was second with score of 0.7035. 
SUCRA scores for other drugs were: Bisoprolol 0.6897, Metoprolol 0.6139, Nebivolol 
0.3704, Bucindolol 0.3519, Enalapriol 0.2635 and Placebo 0.1399. The odds ratios for 
Carvedilol and Atenolol versus placebo were 0.56 (0.43 – 0.71) and 0.54 (0.15 – 1.87), 
respectively. cOnclusiOns: Network meta-analysis shows that Carvedilol ranks 
highest among beta-blockers for reduction in mortality in patients with heart 
failure and reduced ejection fraction.
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Objectives: The National Institute for Health and Care Excellence in the United 
Kingdom (UK) recently issued guidance recommending the non-vitamin k antago-
nist oral anticoagulants (NOACs) rivaroxaban, dabigatran and apixaban for treatment 
and prevention of venous thromboembolism (VTE). An economic evaluation assess-
ing apixaban versus rivaroxaban and dabigatran found apixaban was associated 
with greater quality-adjusted life-years (QALYs) gained at a lower cost. Edoxaban, 
another NOAC, is poised to enter the (ex-United States [US]) market for the same 
indication. This analysis therefore evaluated the cost-effectiveness of apixaban 
compared to low molecular weight heparin (LMWH) followed by edoxaban from 
the perspective of the UK National Health Service. MethOds: A Markov model 
was developed to evaluate the lifetime clinical and economic impact of six-month 
treatment following a VTE event with apixaban versus LMWH/edoxaban. The model 
included the following health states: recurrent VTE, major bleed, clinically relevant 
non-major bleed, chronic thromboembolic pulmonary hypertension, and death. 
Transition rates among health states were based upon AMPLIFY and AMPLIFY-EXT 
clinical trial data, network meta-analyses, and UK life tables. Cost and utilities 
were based on published estimates. Price parity with apixaban was assumed in 
the absence of any pricing information for edoxaban. Outcomes were life-years 
gained, QALYs gained, costs estimated in 2012 British pounds, and the incremental 
cost-effectiveness ratio (ICER). Results: Six-month treatment with apixaban was 
predicted to increase life expectancy and QALYs as compared to LMWH/edoxaban 
over a lifetime horizon. When these treatments were priced at parity, apixaban 
was associated with cost-savings due to avoided bleeds and higher cost of LMWH. 
Dominance was maintained even when edoxaban was priced at an 18% discount 
disease and obesity, as well as between sHTG and diabetes and acute pancreati-
tis. Patients with HTG received treatment with statins, fibrates, and omega-3 for-
mulations, including omega-3 ethyl esters and omega-3 fatty acids. Combination 
therapy was typically more effective at reducing TG levels than monotherapy. 
Economic data were reported only for sHTG patients in the United States (US) 
with annual direct costs from $8,000 -$9,000. Patients with TG levels > 17 mmol/L 
observed a marked increase in the total all-cause medical and pharmacy costs, 
which reached $12,642/year. Prescription omega-3 ethyl esters were cost-effective 
in the US based on a simulation model estimating $47,000/quality-adjusted life-year 
using a threshold of $50,000. Only two identified studies reported patient-centered 
outcomes. cOnclusiOns: High HTG prevalence in various regions indicates dis-
ease burden is not effectively managed by current therapies and suggests a need for 
new treatments. Treating HTG and associated comorbidities results in a substantial 
economic burden. Further research is needed on the patient-centered burden of 
HTG and the economic impact of this disease, specifically in non-US locations and 
patients with TG levels ≥ 2.26 and < 5.6 mmol/L.
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Objectives: Atrial fibrillation is the most common arrhythmia, affecting more 
than 4.5 million people in Europe. Owing to recent introduction of novel oral anti-
coagulant (NOACs) treatments in Germany, there is a need to generate real-world 
evidence on the profiles of patients with NVAF prescribed with such therapies. This 
study aimed to describe demographic and clinical characteristics of patients with 
NVAF newly prescribed NOACs in Germany. MethOds: Retrospective cohort study 
of patients with NVAF who were newly prescribed with NOACs (index prescription) 
between December 2012 and October 2014, using German primary care data from 
IMS Disease Analyzer. We calculated summary statistics of demographic and clini-
cal characteristics in each NOAC therapy group. Results: Overall, 2,678 patients 
initiated apixaban, 2,696 dabigatran, and 9,562 rivaroxaban in the study period. At 
time of index NOAC initiation, mean age was 75.9 years (standard deviation 10.0; 
interquartile range 71-83) for apixaban, 74.5 (SD 10.3; IQR 69-82) for dabigatran, and 
74.7 (SD 10.4; IQR 69-82) for rivaroxaban. Across all NOAC therapies, around half 
were men and approximately 80% lived in West Germany. Patients on apixaban 
had higher rates of stroke risk factors such as hypertension (88.2% vs. 86.4% and 
85.4% for dabigatran and rivaroxaban, respectively); vascular diseases (61.3% vs. 
57.2% and 58.5%); and congestive heart failure (43.5% vs. 39.6% and 40.9%); and 
higher rate of bleeding history (30.0% vs. 27.1% and 27.8%). cOnclusiOns: In 
routine clinical practice in Germany, patients newly treated with NOACs were 
elderly and frequently had comorbidities of cardiovascular importance such 
as hypertension and vascular diseases. Patients on apixaban had higher rates 
of stroke risk factors and bleeding history, which are likely to impact treat-
ment patterns and outcomes observed in this population. Future comparative 
effectiveness research across NOACs should account for channeling in patient 
profiles.
PCV10
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Objectives: To review trends in pulmonary embolism-related discharges and 
understand sociodemographic and seasonal factors correlated with a PE diagnosis 
among hospitalized Spanish patients. MethOds: Using hospital discharge data 
from the Encuesta de Morbilidad Hospitalaria we analyzed trends in PE-related 
hospital discharges in Spanish hospitals from 2008 to 2011. PE was defined based on 
principal diagnosis ICD-9 codes 41511 (Iatrogenic pulmonary embolism and infarc-
tion), 41512 (septic pulmonary embolism), 41513 (saddle embolus of pulmonary 
artery), and 41519 (other pulmonary embolism and infarction). The principal diag-
nosis was established to be the primary reason the patient was hospitalized. Results 
were stratified by age, sex, province and season of the year. We used log-binomial 
and logistic regression models to evaluate the relationship between these char-
acteristics and a diagnosis of PE. Results: Of the 18,317,000 hospital admissions 
over the 4-year period, 56,600 (0.31%) were primarily PE-related. The proportion of 
PE diagnosis of all hospitalizations remained steady, ranging from 0.28%- 0.34%. PE 
risk was similar among males and females; risk ratio (RR) 1.03 95% CI (1.04-1.07). 
PE-related hospitalizations increased with age however, rates were higher in men 
65 years and younger than their female counterparts and higher in women 70 and 
older than their male counterparts. The greatest change (30% increase) in diagnosis 
from 2008-2011 was among 40-59 year olds and people over 80. We found a seasonal 
variation in PE diagnosis, with lowest rates of diagnosis in April to July in both 
males and females, over the 4-year period. PE hospitalization rates were two times 
higher in the northern than southern regions RR 1.82(1.76-1.88). cOnclusiOns: 
Age, gender, geographic location and month of the year were correlated with diag-
nosis of PE among hospitalized Spanish patients. A future area of research is to 
clarify these relationships and determine possible interventions to reduce PE in 
these populations.
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square and Student t- tests for categorical and continuous variables, respectively. 
The effect of the selection of P2Y12 drugs on the time-to-first hospital re-admission 
was determined using a Cox-proportional hazard regression model. We controlled 
for potential confounders whose p-values at the baseline comparison were less 
than 0.1. Results: A total of 9698 patients received PCI with a primary diagnosis 
of ACS, and started prasugrel (n= 7095) or ticagrelor (n= 2603). The ticagrelor treated 
group was older and more likely to have a diagnosis of intracranial hemorrhage, 
cerebrovascular accident, cardiac disorders and renal disorders than the prasugrel 
group. The observed 365-day hazard ratio (HR) of re-admission for ticagrelor was 
1.056 [95% CI: 0.867, 1.285] which was unchanged after controlling for the potential 
confounders (HR: 1.056 [95% CI: 0.867 – 1.286]). cOnclusiOns: The selection of 
third-generation antiplatelet agents following PCI was not associated with a clini-
cally or statistically significant reduction in hospital-readmission.
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bAckgROund: In October 2011, the National Institute for Health and Care 
Excellence (NICE) recommended the use of ticagrelor in adult patients presenting 
with acute coronary syndrome (ACS) in England and Wales. The relative effective-
ness and cost-effectiveness of ticagrelor compared to clopidogrel—the current 
standard of care in the NHS—were based on results from one large multicentre 
study including over 18,000 ACS patients. Patients were recruited from October 
2006 through to July 2008 and primary trial data analysis, published in September 
2009, demonstrated that ticagrelor significantly reduced the rate of death, myo-
cardial infarction (MI), and/or stroke versus clopidogrel. Delays in completing 
and reporting on RCTs can impede access to new valuable treatments; however, 
data simulation may allow for the continuous modelling of trial results and sup-
port early HTA submissions. Objectives: Using a data simulation approach to 
estimate the relative effectiveness of ticagrelor vs. clopidogrel from recruitment 
to final analysis, we explore whether a trial design with shorter follow-up or the 
publication of an interim analysis could have resulted in a positive NICE decision 
at an earlier time point. MethOds: Time-to-event data was extracted from pub-
lished Kaplan-Meir curves and individual patient data was simulated assuming 
censoring and recruitment distributions. The relative effectiveness of ticagrelor 
was assessed as a continuum from 2006 to 2009; and the probability of ticagrelor 
being cost-effective in the UK was also evaluated over time using a trial-based 
economic model. Results: Despite increased uncertainty around the probabili-
ties of death, MI and stroke estimated from immature trial data; results suggest 
that ticagrelor was a cost-effective alternative to clopidogrel before the original 
completed 12 months follow-up. cOnclusiOns: Data simulation allowed us to 
evaluate HTA outcomes prior to the original planned analysis which, in retrospect, 
could have led to an earlier NICE recommendation for ticagrelor in ACS.
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Objectives: To compare the cost and effectiveness of aspirin and clopidogrel 
in ischemic stroke(IS) patients from data of Beijing medical insurance data-
base. MethOds: We randomly selected 10% of patients diagnosed as IS the 
first time during January 2012- December 2012 and then followed their inpatient 
records and prescription records to September 2013 from Beijing urban employees 
and residents medical insurance database. We divided these patients into 5 groups 
according to their drug utilization records during the observation period. Patients 
were divided into 5 groups according to the proportion of aspirin prescription by 
100.0%, 60.1-99.9%, 40.0-60.0%, 0-39.9% and 0(clopidogrel only). We compared the 
rate of recurrences, cost of anti-platelet drugs and rate of hemorrhage events in 
different drug utilization groups. The Kruskal-Wallis test and Bartlett’s test were 
used in the analysis. Results: 4301 patients were identified(age 68.29±13.94, 
male 63.19%), 1477 (34.34%) patients used aspirin only, 1938 (45.06%) patients used 
60-100% aspirin, 465 (10.81%) patients used 40-60% aspirin, 335 (7.78%) patients 
used aspirin 0-40% and 86 (2.01%) patients used clopidogrel only. patients with 
only aspirin recurred less than patients with both aspirin and clopidogrel pre-
scription, patients with 60-100% aspirin prescription recurred less than patients 
with less aspirin prescription. patients with aspirin prescription only spent less 
on anti-platelet drugs than that of patients with both aspirin and clopidogrel 
prescription(p< 0.01),. The rates of hemorrhage events for IS patients of different 
drug groups showed no significant difference(p> 0.05). cOnclusiOns: IS patients 
used more aspirin for anti-platelet treatment. The cost of anti-platelet drugs and 
rate of recurrence of patients who used aspirin only was lower, while no significant 
difference was found in hemorrhage events rates among different drug groups.
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Edwards SJ, Wakefield V, Karner C
BMJ, London, UK
Objectives: New oral anticoagulants (NOACs) are available for the treatment and 
prevention of VTE but evidence on their clinical effectiveness compared with existing 
treatments is limited. This research compared the clinical effectiveness of dabigatran, 
rivaroxaban, adjusted standard dose warfarin (warfarin), and low molecular weight 
heparin (LMWH) in people with active cancer following VTE. This research was con-
to apixaban. One-way and probabilistic sensitivity analyses indicated that model 
conclusions were robust over a wide range of inputs. cOnclusiOns: Apixaban 
appears to be a dominant alternative to LMWH/edoxaban for the treatment and 
prevention of VTE.
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Objectives: Uncontrolled hypertension remains a major problem for health care 
systems worldwide, being strictly related to a persistently elevated burden of car-
diovascular morbidity and mortality. Because of the multifactorial nature of hyper-
tension, most patients require combination therapy to achieve blood pressure (BP) 
control. This analysis aimed to further investigate the effectiveness of amlodipine/
valsartan/hydrochlorothiazide (A+V+H) single-pill combination in lowering the BP 
of hypertensive patients, previous assessed in an observational study. MethOds: 
This analysis was based on a data registry collected in a prospective, open-
label, observational study conducted in 7132 patients diagnosed with essential 
hypertension and for whom treatment with A+V+H was indicated according to 
clinical practice. The observational period was 3 months. Descriptive analysis, 
hypothesis testing and linear regression models were performed. Results: The 
reduction in systolic blood pressure (RSP) between baseline and last visit was 
23.73±17.51 (mean±SD) while the reduction in diastolic blood pressure (RDP) was 
11.34±10.63 mmHg (mean±SD). A t-test showed that both reductions are statisti-
cally significant (p< < 0.001). Multiple linear regression models were fitted to RSP 
and RDP, to assess the influence of patients’ characteristics, comorbidities and 
previous treatment (R2 = 0.11 and 0.13, respectively). cOnclusiOns: Although 
significant, the model covariates were not sufficient to explain the reduction 
in SP and DP (11% and 13% explained, respectively) found between the base-
line and last visit. Since most of the variables known as relevant to character-
ize hypertension were included in the study, the results allow to conclude that 
reduction found is mainly explained by the treatment with A+V+H single-pill 
combination.
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Objectives: New oral anticoagulants (NOACs) are available for the treatment 
and prevention of VTE, but evidence on their clinical effectiveness compared 
with existing treatments is limited. We compared the clinical effectiveness of 
edoxaban, dabigatran and rivaroxaban using adjusted standard dose warfarin 
(warfarin) as a common comparator in patients with index DVT. This research 
was conducted during a review of the company’s submission (CS) to the National 
Institute for Health and Care Excellence (NICE) Single Technology Appraisal pro-
gramme for the oral direct factor Xa inhibitor, edoxaban. MethOds: Randomised 
controlled trials (RCTs) for inclusion were identified using the CS for edoxaban 
(as part of Technology Appraisal [TA] 662). We assessed RCTs for comparability 
based on patient population, disease severity, and treatments received. We con-
ducted a Bayesian MTC and explored fixed and random effects models. Odds ratio 
(OR) was the summary statistic for VTE recurrence and major bleed. Results: 
The network of five RCTs formed a “radiating star”. The Deviance Information 
Criterion (DIC) and the residual deviance with the number of unconstrained 
data points for both outcomes showed fixed and random effects models were 
an equally good fit. Due to the small number of studies and the shape of the 
network, the results from the fixed effects model are presented. Results com-
pared to warfarin were (OR> 1 favours warfarin): VTE recurrence edoxaban OR 0.95 
(95% Credible Interval [95%CrI]: 0.62–1.40), dabigatran OR 1.27 (95%CrI: 0.78–1.97), 
rivaroxaban OR 0.64 (95%CrI: 0.40–0.96); major bleed edoxaban OR 0.84 (95%CrI: 
0.48–1.35), dabigatran OR 0.83 (95%CrI: 0.50–1.31), rivaroxaban OR 0.92 (95%CrI: 
0.37–1.90). cOnclusiOns: Rivaroxaban demonstrated a 36% reduction in risk 
of VTE recurrence compared to warfarin that was statistically significant at the 
5% level. We did not identify other significant differences either when comparing 
NOACs to warfarin or when comparing NOACs with each other.
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Objectives: Randomized controlled trials have provided evidence that both 
prasugrel and ticagrelor can reduce complications in patients with acute coronary 
syndrome (ACS). However, no head-to-head comparisons were performed between 
these third-generation drugs. The aim of this study was to compare the hospital 
admission rates between patients receiving ticagrelor and prasugrel during post 
percutaneous coronary intervention (PCI). MethOds: A Retrospective cohort 
study was designed to compare all cause hospitalization over 365 days post PCI 
discharge. Patients who received PCI with an ACS hospitalization between January 
2012 to December 2013 were extracted from the Truven Health Analytics MarketScan 
database. Eligible patients filled either a prasugrel or ticagrelor prescription within 
14 days from the discharge date. To be included in the analytic cohort, patients 
needed to be continuously enrolled in the data over six-months prior to the index 
admission, and comorbid conditions over that period were assessed using Chi-
